The usage rates of diabetes medications were as follows: biguanides, 62.8%; sodium-glucose cotransporter 2 inhibitors, 51.3%; dipeptidyl peptidase IV inhibitors, 44.2%; glucagon-like peptide 1 receptor agonists, 31.0%; sulfonylureas, 16.8%; thiazolidinediones, 15.9%; insulin, 15.0%; α-glucosidase inhibitors, 13.3%; meglitinides, 12.4%; and imeglimin, 3.5% (multiple responses allowed) (Table 1). Here, SLC5A2 is linked to diabetes mellitus.